Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.18949 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Nina Magnolo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: La Roche-Posay.
Abstract (Originalsprache)
Background
Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients ‘plus’ and eudermic cleansers for all AD patients to improve the skin barrier and provide anti‐irritant and anti‐pruritic effects.
Objectives
To investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient ‘plus’ balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers.
Methods
In a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score ≥ 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient ‘plus’ after pre‐cleaning with the syndet (Emollient ‘plus’ group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires.
Results
Included were 57 patients with mean age of 38 years (range 19–70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29–1099 g) and 613.2 g (range 97–2565 g) for the Emollient ‘plus’ versus the Control, respectively ( p = 0.0277). After 10 weeks, subjects in the Emollient ‘plus’ had a significantly greater reduction in current pruritus ( p = 0.0277) and a greater reduction in some DLQI items compared to the Control group.
Conclusions
In patients with moderate to severe AD receiving systemic treatment, the Emollient ‘plus’ regimen significantly improved pruritus and quality of life items compared to the control, while using 23% less product over a 10‐week period. These results stress the importance of daily use of emollients, especially emollients ‘plus’ to improve signs, symptoms and quality of life in patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Münster, Münster, Germany.
- IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.
- Department of Dermatology, Fachklinik Bad Bentheim, Bad Bentheim, Germany.
- Dermatology and Allergology Clinic, University of Frankfurt, Frankfurt, Germany.
- Institute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany.
- Clinic for Dermatology, Venereology, and Allergology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
ORCID-Profile: Thomas Jaenicke, Diamant Thaçi, Andreas Pinter, Delphine Kerob, Samir Salah, Thomas A Luger
Förderung
- La Roche-Posay
Zitieren
APA
Magnolo, N., Jaenicke, T., Tsianakas, A., Czech, W., Thaçi, D., Pinter, A., Kerob, D., Salah, S., & Luger, T. A. (2023). Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18949
Vancouver
Magnolo N, Jaenicke T, Tsianakas A, Czech W, Thaçi D, Pinter A, et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18949
BibTeX
@article{Magnolo2023,
author = {Magnolo, Nina and Jaenicke, Thomas and Tsianakas, Athanasios and Czech, Wolfgang and Thaçi, Diamant and Pinter, Andreas and Kerob, Delphine and Salah, Samir and Luger, Thomas A},
title = {Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.18949}
}
EUVIMED